Failure of papaverine to alter l-dopa-influenced gh and prl secretion

David S. Cooper, Laurence S. Jacobs

Research output: Contribution to journalArticlepeer-review


Papaverine150 mg BID for 2 weeks, a dose which produced marked clinical impairment in Parkinsonian patients taking L-Dopa, failed to alter L-Dopa-stimulated GH secretion or L-Dopainhibited PRL secretion in 6 normal volunteers. Failure to demonstrate an inhibitory effect of papaverine on dopaminergic hypothalamic-pituitary systems, despite its inhibition of striatal dopaminergic pathways, may imply qualitative or quantitative functional differences between hypothalamic and striatal dopaminergic systems.

Original languageEnglish (US)
Pages (from-to)585-587
Number of pages3
JournalJournal of Clinical Endocrinology and Metabolism
Issue number3
StatePublished - Mar 1977
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Failure of papaverine to alter l-dopa-influenced gh and prl secretion'. Together they form a unique fingerprint.

Cite this